{
  "patent_number": "US 12734137",
  "country": "US",
  "title": "Treating Severe Childhood Epilepsy with Fenfluramine",
  "original_title": "Methods of treating Lennox-Gastaut Syndrome using fenfluramine",
  "summary": "This patent describes a specific way to treat Lennox-Gastaut Syndrome, a severe form of childhood epilepsy, by giving patients a controlled dose of the drug fenfluramine.",
  "what_it_does": "This patent describes a method for treating or preventing symptoms of Lennox-Gastaut Syndrome (LGS), a severe type of epilepsy, in a patient. The method involves giving the patient an effective dose of fenfluramine or its pharmaceutically acceptable salt. Specifically, the patent mentions a preferred dosage range for LGS patients of less than about 2.0 to about 0.01 milligrams per kilogram of body weight per day. For example, a child previously diagnosed with LGS would receive fenfluramine within this precise daily dosage range to help manage their seizures.",
  "what_it_does_not_cover": [
    "Does not cover using fenfluramine to treat other types of epilepsy or medical conditions not identified as Lennox-Gastaut Syndrome.",
    "Does not cover treating Lennox-Gastaut Syndrome with other medications that are not fenfluramine or its pharmaceutically acceptable salts.",
    "Does not cover administering fenfluramine at dosages outside the specified range of less than about 2.0 to about 0.01 mg/kg/day for LGS.",
    "Does not cover methods of preventing LGS symptoms that do not involve administering fenfluramine."
  ],
  "filed": "2020-05-01",
  "granted": "2026-09-15",
  "expires": null,
  "status": "active",
  "holder": null,
  "holder_url": null,
  "inventors": [],
  "times_cited": 0,
  "tags": [
    "pharmaceutical",
    "biotech"
  ],
  "abstract": "A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.",
  "url": "https://patentbrief.org/patent/us/12734137/methods-of-treating-lennox-gastaut-syndrome-using-fenfluramine",
  "markdown_url": "https://patentbrief.org/patent/us/12734137/methods-of-treating-lennox-gastaut-syndrome-using-fenfluramine/md",
  "google_patents_url": "https://patents.google.com/patent/US12734137",
  "relatedPatents": []
}